塞力医疗更正参股子公司增资及投资公告股权结构

Group 1 - The company issued a correction announcement regarding its investment in a subsidiary, which was initially disclosed on September 18 [1] - The correction involves changes in the shareholding structure of the target company post-acquisition, with "Cyrus Medical" reducing its stake from 49.00% to 41.00%, while "Weixin Biotechnology" increased its stake from 41.00% to 49.00% [1] - The company apologized for any inconvenience caused by the correction and stated it would enhance its information disclosure review process [1]